Drugs / IODINE I 131 APAMISTAMAB
IODINE I 131 APAMISTAMAB
also known as
131-I Apamistamab · Iomab-B · Apamistamab iodine i-131 · apamistamab-I131 · I 131 moab bc8 · I-131-BC8 · Iodine (131i) apamistamab · Iodo (131i) apamistamab
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04512716 | Feb 2021 → Jan 2027 expected | B-cell lymphoma, unclassifiable, with features intermediate between diffuse large b-cell lymphoma and classical Hodgkin lymphoma, diffuse large B-cell lymphoma activated B-cell type, diffuse large B-cell lymphoma germinal center B-cell type, high grade B-cell lymphoma | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT07015684 | Apr 2025 → Mar 2030 expected | sickle cell disease | Columbia University | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06768905 | Apr 2025 → May 2029 expected | diffuse large B-cell lymphoma | University of Texas Southwestern Medical Center | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02665065 | Jun 2016 → Jun 2022 overdue | acute myeloid leukemia | Actinium Pharmaceuticals | Active not recruiting | No outcome recorded |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IODINE I 131 APAMISTAMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297997 ↗ |
| Known as | 131-I Apamistamab | “131I-apamistamab is a drug construct consisting of the apamistamab monoclonal antibody (mAb) and radioactive isotope iodine 131 (131I).” NCT07015684 ↗ |
| Known as | Apamistamab iodine i-131 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297997 ↗ |
| Known as | apamistamab-I131 | “Iomab-B [apamistamab-I131] is currently studied in the registration-type phase 3 SIERRA trial” PMID 35350938 ↗ Mar 2022 |
| Known as | I 131 moab bc8 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297997 ↗ |
| Known as | I-131-BC8 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297997 ↗ |
| Known as | Iodine (131i) apamistamab | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297997 ↗ |
| Known as | Iodo (131i) apamistamab | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297997 ↗ |
| Known as | Iomab-B | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06768905 ↗ |
| Modality | Monoclonal antibody | “apamistamab monoclonal antibody (mAb)” NCT07015684 ↗ |
| Route | Intravenous | “131I-apamistmab will be given via intravenous (IV) infusion.” NCT07015684 ↗ |